Venous Thromboembolism in Medical Patients - The Scope of the Problem

Seminars in Thrombosis and Hemostasis

Volumn 29, Issue SUPPL. 1, 2003, Pages 17-21

  Haas, Sylvia ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Medical patients; Prevention; Risk of deep venous thrombosis; Thromboembolism

Indexed keywords

ANTITHROMBOCYTIC AGENT;

ACCURACY; AGING; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DEEP VEIN THROMBOSIS; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; EVIDENCE BASED MEDICINE; HEART INFARCTION; HOSPITAL PATIENT; HUMAN; HYPERCOAGULABILITY; INTENSIVE CARE UNIT; MALIGNANT NEOPLASTIC DISEASE; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESPIRATORY DISTRESS; RISK ASSESSMENT; RISK FACTOR; STROKE; SURGICAL RISK; VENOUS THROMBOEMBOLISM;

ADULT; AGED; AGING; CASE-CONTROL STUDIES; COHORT STUDIES; COMORBIDITY; HUMANS; INTERNAL MEDICINE; MIDDLE AGED; NEOPLASMS; PREVALENCE; RISK ASSESSMENT; RISK FACTORS; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 0348047549     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (42)

1. Goldhaber SZ. Clinical overview of venous thromboembolism. Vasc Med 1998;3:35-40
2. Stratton MA, Anderson FA, Bussey HI, et al. Prevention of venous thromboembolism: adherence to the 1995 American College of Chest Physicians consensus guidelines for surgical patients. Arch Intern Med 2000;160:334-340
3. Sandler DA, Martin JF. Autopsy-proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med 1989;82:203-205
4. Anderson FA Jr, Wheeler HB. Physician practices in the management of venous thromboembolism: a community-wide survey. J Vasc Surg 1992;16:707-714
5. Goldhaber SZ, Hennekens CH, Evans DA, Newton EC, Godleski JJ. Factors associated with correct antemortem diagnosis of major pulmonary embolism. Am J Med 1982;73: 822-826
6. Nicolaides AN, Breddin HK, Fareed J, et al. Prevention of venous thromboembolism. International Consensus Statement. Guidelines compiled in accordance with the scientific evidence. Int Angiol 2001;20:1-37
7. Geerts WH, Heit JA, Clagett GP, et al. Prevention of venous thromboembolism. Chest 2001;119(suppl 1):132S-175S
8. Hirsh DR, Ingenito EP, Goldhaber SZ. Prevalence of deep venous thrombosis among patients in medical intensive care. JAMA 1995;274:335-337
9. Fraisse F, Holzapfel L, Couland JM, et al. Nadroparin in the prevention of deep vein thrombosis in acute decompensated COPD. The Association of Non-University Affiliated Intensive Care Specialist Physicians of France. Am J Respir Crit Care Med 2000;161:1109-1114
10. Samama MM, Cohen AT, Darmon JY, et al. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group. N Engl J Med 1999;341:793-800
11. Mismetti P, Laporte-Simitsidis S, Tardy B, et al. Prevention of venous thromboembolism in internal medicine with unfractionated or low-molecular- weight heparins: a meta-analysis of randomised clinical trials. Thromb Haemost 2000;83:14-19
12. Yirchow R. Phlogose und Thrombose im Gefässystem. Gesammelte Abhandlungen Eur Wissenschaftlichen Medicin. Berlin: von Meininger III; 1856:458-635
13. Jafri SM, Ozawa T, Mammen E, et al. Platelet function, thrombin and fibrinolytic activity in patients with heart failure. Eur Heart J 1993;14:205-212
14. Silverstein MD, Heit JA, Mohr DN, et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25 years population-based study. Arch Intern Med 1998;158: 585-593
15. Martinelli I. Risk factors for venous thromboembolism. Thromb Haemost 2001;86:395-403
16. Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost 2001;86:452-463
17. Anderson FA, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT study. Arch Intern Med 1991;151:933-938
18. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP study group. Groupe d'étude de la thrombose de Bretagne Occidentale. Thromb Haemost 2000;83:657-660
19. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Predictors of survival after deep vein thrombosis and pulmonary embolism: a population based, cohort study. Arch Intern Med 1999;159:445-453
20. Tracy RP, Bovill EG, Fried LP, et al. The distribution of coagulation factors VII and VIII in adults over 65 years. Results from the Cardiovascular Health Study. Ann Epidemiol 1992; 2:509-519
21. Ershler WB. Interleukin-6: a cytokine for gerontologists. J Am Geriatr Soc 1993;41:176-181
22. Brozovic M, Chakrabarti R, Stirling Y, et al. Factor V in an industrial population. Br J Haematol 1976;33:543-550
23. Köster T, Blann D, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII and effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345:152-155
24. Lowe GD, Rumley A, Woodward M, et al. Epidemiology of coagulation factors, inhibitors and activation markers: the third Glasgow MONICA survey. Illustrative reference ranges by age, sex and hormone use. Br J Haematol 1997;97:775-784
25. Bauer KA, Weiss LM, Sparrow D, Vokonas PS, Rosenberg RD. Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study. J Clin Invest 1987;80:1527-1534
26. Ofosu FA, Craven S, Dewar L, et al. Age-related changes in factor VII proteolysis in vivo. Br J Haematol 1996;94:407-412
27. Wilkerson WR, Sane DC. Aging and thrombosis. Semin Thromb Hemost 2002;28:555-567
28. Sakkinen PA, Cushman M, Psaty BM, et al. Correlates of antithrombin, protein C, protein S, and TFPI in a healthy elderly cohort. Thromb Haemost 1998;80:134-139
29. Gleerup G, Winther K. The effect of aging on platelet function and fibrinolytic activity. Angiology 1995;46:715-718
30. Mehta J, Mehta P, Lawson D, Saldeen T. Plasma tissue plasminogen activator inhibitor levels in coronary artery disease: correlation with age and serum triglyceride concentrations. J Am Coll Cardiol 1987;9:263-268
31. Schatteman KA, Goossens FJ, Scharpe SS, Neels HM, Hendriks DF. Assay of procarboxypeptidase U, a novel determinant of the fibrinolytic cascade, in human plasma. Clin Chem 1999;45:807-813
32. Cogo A, Bernardi E, Prandoni P, et al. Acquired risk factors for deep-vein thrombosis in symptomatic outpatients. Arch Intern Med 1994;154:164-168
33. Grady D, Wenger NK, Herrington D, et al. Postmenopausal hormone therapy increases the risk for venous thromboembolic disease. The Heart and Estrogen/Progestin Replacement Study. Ann Intern Med 2000;132:689-696
34. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O'Fallon WM, Melton LJ. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based, case-control study. Arch Intern Med 2000;160:809-815
35. Agnelli G. Venous thromboembolism and cancer: a two-way clinical association. Thromb Haemost 1997;78:117-120
36. Ambrus JL, Ambrus CM, Mink IB, Pickren JW. Causes of death in cancer patients. J Med 1975;6:61-64
37. Johnson MJ, Sherry K. How do palliative physicians manage venous thromboembolism? Palliat Med 1997;11:462-468
38. Scates SM. Diagnosis and treatment of cancer-related thrombosis. Semin Thromb Hemost 1992;18:373-379
39. Harrington KJ, Bateman AR, Syrigos KN, et al. Cancer-related thromboembolic disease in patients with solid tumours: a retrospective analysis. Ann Oncol 1997;8:669-673
40. Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med 1998;338:1202-1211
41. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med 2000;160:3415-3420
42. Haas S. Venous thromboembolic risk and its prevention in hospitalized medical patients. Semin Thromb Hemost 2002; 28:577-583